×

Tonghua Dongbao 2021 milestones—value-driven innovation and R&D

Date:2022-01-27
Author:东宝
Views:1

2021 was a bumper year for Tonghua Dongbao's innovation and transformation. The Company is fast-tracking its biomedical innovation by fully focusing on the R&D of novel drugs, expanding R&D pipelines, and improving R&D efficiency. It is also extending its reach to the treatments of endocrine diseases other than diabetes. At the same time, the Company is striving to build a high-quality, innovative R&D team, which now consists of about 400 professionals with a doctorate or master's degree.

 

January 2021

Established the Hangzhou Novel Drug R&D Center


March 2021

Signed a memorandum of understanding on strategic cooperation and a cooperation agreement with WuXi AppTec in the development of three Class 1 new diabetes drugs


April 2021

Announced the NMPA acceptance of the NDA for the world's first triple-target inhibitor (SGLT1/SGLT2/DPP4)


June 2021

Announced the NMPA acceptance of the NDA for repaglinide tablets.

Got the nod for the clinical trial application for the world's first triple-target inhibitor (SGLT1/SGLT2/DPP4).


July 2021

Signed a cooperation agreement in the development of two Class 1 new drugs for the treatment of gout and hyperuricemia.

Announced NMPA acceptance of the NDA for insulin aspart 50 and 30 injections.


September 2021

Got the nod for the sitagliptin phosphate tablets.


October 2021

Announced NMPA acceptance of the clinical trial application for the URAT1 inhibitor (treatment of gout and hyperuricemia).

Got the nod for the parallel phase III and phase I clinical trials of BC Lispro.

Got the nod for the sitagliptin metformin tablets (II).

Got the nod for the insulin aspart injection.


December 2021

Got the nod for the clinical trial application for the URAT1 inhibitor (treatment of gout and hyperuricemia).

Announced the NMPA acceptance of the clinical trial application for BC Combo (THDB0207 injection).

 

Tonghua Dongbao will continue to keep a finger on the pulse of the cutting-edge and key technologies in diabetes and endocrine treatment, in a bid to build a world-class R&D and commercialization platform. Guided by the philosophy of "Persist in innovation, build a global brand", the Company will stick to the strategy of transformation and innovation, inspire talent's creativity, facilitate fast, comprehensive, in-depth, and innovative R&D, and advance an innovation-driven development pattern to promote high-quality business growth.


0